成纤维细胞生长因子21在非酒精性脂肪性肝病中的应用现状与展望

金雷钢; 耿磊落; 徐爱民

doi:10.3969/j.issn.1001-5256.2021.06.006

成纤维细胞生长因子21在非酒精性脂肪性肝病中的应用现状与展望

DOI: 10.3969/j.issn.1001-5256.2021.06.006

金雷钢^{a, b, c},
耿磊落^{a, b},
徐爱民^{a, b, c, ,}

a.
香港大学生物医药技术国家重点实验室，香港特别行政区 999077
b.
香港大学内科系，香港特别行政区 999077
c.
香港大学药理与药剂系，香港特别行政区 999077

基金项目:

国家自然基金面上项目 (82070860)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：金雷钢负责收集分析资料，撰写论文；耿磊落负责论文修改；徐爱民拟定写作思路，指导文章撰写并最后定稿。

详细信息

作者简介:
金雷钢(1990—)，男，博士，主要从事代谢性疾病研究

通信作者:
徐爱民，amxu@hku.hk

中图分类号: R575.5
计量
- 文章访问数: 969
- HTML全文浏览量: 549
- PDF下载量: 124
- 被引次数: 0
出版历程
- 收稿日期: 2021-04-03
- 录用日期: 2021-04-13
- 出版日期: 2021-06-20

Current status and perspectives of fibroblast growth factor 21 in nonalcoholic fatty liver disease

Leigang JIN^{a, b, c},
Leiluo GENG^{a, b},
Aimin XU^{a, b, c
, ,}

a.
State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong 999077, China
b.
Department of Medicine, The University of Hong Kong, Hong Kong 999077, China
c.
Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong 999077, China

摘要

摘要: 成纤维细胞生长因子21(FGF21)是一种主要由肝细胞产生的分泌因子，在维持机体能量代谢平衡、调节胰岛素敏感性等过程中发挥重要作用。临床研究显示，血液FGF21在肥胖相关的非酒精性脂肪性肝病(NAFLD)患者中明显升高，是预测NAFLD发生发展的可靠生物标志物。在动物模型及NAFLD患者中，注射外源性FGF21可明显缓解该病病理进程。从FGF21的生物学特性出发，阐述其调控肝代谢及减轻肝损伤的分子作用机制，并着重讨论FGF21类似物及其受体激动剂在临床试验治疗NAFLD及非酒精性脂肪性肝炎的最新进展，以及遇到的主要问题与挑战，并展望其诊治NAFLD的应用前景。
- 成纤维细胞生长因子21 /
- 非酒精性脂肪性肝病 /
- 代谢综合征X
Abstract: Fibroblast growth factor 21 (FGF21) is a peptide hormone predominantly secreted by the liver and plays a crucial role in maintaining whole-body energy metabolism and regulating insulin sensitivity. A large number of clinical studies have demonstrated that serum FGF21 levels are increased in obese patients with non-alcoholic fatty liver disease (NAFLD), and high circulating FGF21 is a sensitive biomarker for predicting the onset and progression of NAFLD. Injection of exogenous FGF21 can effectively alleviate pathological process in both animal models and NAFLD patients. This review aims to describe the molecular mechanism underlying the hepatoprotective effects of FGF21; to summarize the current data and challenges of the clinical trials on FGF21 analogs and receptor agonists in the treatment of NAFLD and nonalcoholic steatohepatitis (NASH); and to speculate the future directions of FGF21 as a diagnosis and treatment for NAFLD.
- Fibroblast Growth Factor 21 /
- Non-alcoholic Fatty Liver Disease /
- Metabolic Syndrome X

HTML全文

图 1 FGF21调控肝脏代谢及减轻肝损伤的直接或间接作用

注：肝脏生成的FGF21通过血液循环到达机体各组织。在白色脂肪组织中，FGF21促进脂联素的生成和分泌，后者与肝脏中的脂联素受体结合，改善肝糖脂代谢；FGF21也可以通过作用于神经系统，调节肝代谢，维持机体葡萄糖稳态；另外，肝脏产生的FGF21也可以作用于肝脏本身，促进脂肪酸氧化，降低脂质合成，增加肝脏胰岛素敏感性，从而减缓肝损伤。

下载: 全尺寸图片幻灯片

参考文献(44)

[1]	HUI Q, JIN Z, LI X, et al. FGF family: From drug development to clinical application[J]. Int J Mol Sci, 2018, 19(7): 1875. DOI: 10.3390/ijms19071875.
[2]	NISHIMURA T, NAKATAKE Y, KONISHI M, et al. Identification of a novel FGF, FGF-21, preferentially expressed in the liver[J]. Biochim Biophys Acta, 2000, 1492(1): 203-206. DOI: 10.1016/s0167-4781(00)00067-1.
[3]	KHARITONENKOV A, SHIYANOVA TL, KOESTER A, et al. FGF-21 as a novel metabolic regulator[J]. J Clin Invest, 2005, 115(6): 1627-1635. DOI: 10.1172/JCI23606.
[4]	XU J, LLOYD DJ, HALE C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice[J]. Diabetes, 2009, 58(1): 250-259. DOI: 10.2337/db08-0392.
[5]	KHARITONENKOV A, WROBLEWSKI VJ, KOESTER A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21[J]. Endocrinology, 2007, 148(2): 774-781. DOI: 10.1210/en.2006-1168.
[6]	BADMAN MK, PISSIOS P, KENNEDY AR, et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states[J]. Cell Metab, 2007, 5(6): 426-437. DOI: 10.1016/j.cmet.2007.05.002.
[7]	LIANG Q, ZHONG L, ZHANG J, et al. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting[J]. Diabetes, 2014, 63(12): 4064-4075. DOI: 10.2337/db14-0541.
[8]	LIN Z, PAN X, WU F, et al. Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice[J]. Circulation, 2015, 131(21): 1861-1871. DOI: 10.1161/CIRCULATIONAHA.115.015308.
[9]	TALUKDAR S, ZHOU Y, LI D, et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects[J]. Cell Metab, 2016, 23(3): 427-440. DOI: 10.1016/j.cmet.2016.02.001.
[10]	WONG V, ADAMS LA. Fibroblast growth factor 21 for non-alcoholic steatohepatitis[J]. Lancet, 2019, 392(10165): 2658-2660. DOI: 10.1016/S0140-6736(18)32165-2.
[11]	GOETZ R, BEENKEN A, IBRAHIMI OA, et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members[J]. Mol Cell Biol, 2007, 27(9): 3417-3428. DOI: 10.1128/MCB.02249-06.
[12]	FON TACER K, BOOKOUT AL, DING X, et al. Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse[J]. Mol Endocrinol, 2010, 24(10): 2050-2064. DOI: 10.1210/me.2010-0142.
[13]	LIN Z, TIAN H, LAM KS, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice[J]. Cell Metab, 2013, 17(5): 779-789. DOI: 10.1016/j.cmet.2013.04.005.
[14]	BADMAN MK, KOESTER A, FLIER JS, et al. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis[J]. Endocrinology, 2009, 150(11): 4931-4940. DOI: 10.1210/en.2009-0532.
[15]	GONG Q, HU Z, ZHANG F, et al. Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice[J]. Hepatology, 2016, 64(2): 425-438. DOI: 10.1002/hep.28523.
[16]	POTTHOFF MJ, INAGAKI T, SATAPATI S, et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response[J]. Proc Natl Acad Sci U S A, 2009, 106(26): 10853-10858. DOI: 10.1073/pnas.0904187106.
[17]	LIU Y, ZHAO C, XIAO J, et al. Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury[J]. Sci Rep, 2016, 6: 31026. DOI: 10.1038/srep31026.
[18]	KIM SH, KIM KH, KIM HK, et al. Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress[J]. Diabetologia, 2015, 58(4): 809-818. DOI: 10.1007/s00125-014-3475-6.
[19]	XU P, ZHANG Y, LIU Y, et al. Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways[J]. Toxicol Appl Pharmacol, 2016, 290: 43-53. DOI: 10.1016/j.taap.2015.11.012.
[20]	YE D, WANG Y, LI H, et al. Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1α-mediated antioxidant capacity in mice[J]. Hepatology, 2014, 60(3): 977-989. DOI: 10.1002/hep.27060.
[21]	FOLTZ IN, HU S, KING C, et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex[J]. Sci Transl Med, 2012, 4(162): 162ra153. DOI: 10.1126/scitranslmed.3004690.
[22]	FISHER FM, ESTALL JL, ADAMS AC, et al. Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo[J]. Endocrinology, 2011, 152(8): 2996-3004. DOI: 10.1210/en.2011-0281.
[23]	LAN T, MORGAN DA, RAHMOUNI K, et al. FGF19, FGF21, and an FGFR1/β-Klotho-activating antibody act on the nervous system to regulate body weight and glycemia[J]. Cell Metab, 2017, 26(5): 709-718. e3. DOI: 10.1016/j.cmet.2017.09.005.
[24]	DUSHAY J, CHUI PC, GOPALAKRISHNAN GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease[J]. Gastroenterology, 2010, 139(2): 456-463. DOI: 10.1053/j.gastro.2010.04.054.
[25]	FISHER FM, CHUI PC, ANTONELLIS PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state[J]. Diabetes, 2010, 59(11): 2781-2789. DOI: 10.2337/db10-0193.
[26]	YILMAZ Y, EREN F, YONAL O, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease[J]. Eur J Clin Invest, 2010, 40(10): 887-892. DOI: 10.1111/j.1365-2362.2010.02338.x.
[27]	LI H, FANG Q, GAO F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride[J]. J Hepatol, 2010, 53(5): 934-940. DOI: 10.1016/j.jhep.2010.05.018.
[28]	LI H, DONG K, FANG Q, et al. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: A 3-year prospective study in China[J]. J Hepatol, 2013, 58(3): 557-563. DOI: 10.1016/j.jhep.2012.10.029.
[29]	TUCKER B, MCCLELLAND RL, ALLISON MA, et al. Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease[J]. Atherosclerosis, 2020, 299: 38-44. DOI: 10.1016/j.atherosclerosis.2020.03.009.
[30]	YANG M, XU D, LIU Y, et al. Combined serum biomarkers in non-invasive diagnosis of non-alcoholic steatohepatitis[J]. PLoS One, 2015, 10(6): e0131664. DOI: 10.1371/journal.pone.0131664.
[31]	BARB D, BRIL F, KALAVALAPALLI S, et al. Plasma fibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with obesity and type 2 diabetes[J]. J Clin Endocrinol Metab, 2019, 104(8): 3327-3336. DOI: 10.1210/jc.2018-02414.
[32]	WU L, PAN Q, WU G, et al. Diverse changes of circulating fibroblast growth factor 21 levels in hepatitis B virus-related diseases[J]. Sci Rep, 2017, 7(1): 16482. DOI: 10.1038/s41598-017-16312-6.
[33]	YE D, LI H, WANG Y, et al. Circulating fibroblast growth factor 21 is a sensitive biomarker for severe ischemia/reperfusion injury in patients with liver transplantation[J]. Sci Rep, 2016, 6: 19776. DOI: 10.1038/srep19776.
[34]	GILLUM MP, POTTHOFF MJ. FAP finds FGF21 easy to digest[J]. Biochem J, 2016, 473(9): 1125-1127. DOI: 10.1042/BCJ20160004.
[35]	CHARLES ED, NEUSCHWANDER-TETRI BA, PABLO FRIAS J, et al. Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: Results from a randomized phase 2 study[J]. Obesity (Silver Spring), 2019, 27(1): 41-49. DOI: 10.1002/oby.22344.
[36]	STANISLAUS S, HECHT R, YIE J, et al. A novel Fc-FGF21 with improved resistance to proteolysis, increased affinity toward β-Klotho, and enhanced efficacy in mice and cynomolgus monkeys[J]. Endocrinology, 2017, 158(5): 1314-1327. DOI: 10.1210/en.2016-1917.
[37]	RITCHIE M, HANOUNEH IA, NOUREDDIN M, et al. Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?[J]. Expert Opin Investig Drugs, 2020, 29(2): 197-204. DOI: 10.1080/13543784.2020.1718104.
[38]	STEPHEN AH, PETER JR, BRADLEY LF, et al. Efruxifermin (efx), a long-acting fc-fgf21 fusion protein, administered for 16 weeks to patients with nash substantially reduces liver fat and alt, and improves liver histology: Analysis of a randomized, placebo-controlled, phase 2a study (BALANCED)//AASLD Abstracts (Oral)[J]. Hepatology, 2020, 72, 1(Suppl): 6A-7A. DOI: 10.1002/hep.31578.
[39]	BARUCH A, WONG C, CHINN LW, et al. Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans[J]. Proc Natl Acad Sci U S A, 2020, 117(46): 28992-29000. DOI: 10.1073/pnas.2012073117.
[40]	Late-breaking abstracts-presented at the 70th Annual Meeting of the American Association for the Study of Liver Diseases: The liver meeting^TM 2019[J]. Hepatology, 2019, 70(6): 1477A-1501A. DOI: 10.1002/hep.31033.
[41]	DEPAOLI A, PHUNG V, BASHIR MR, et al. 140-LB: NGM313, a novel activator of b-Klotho/FGFR1c, improves insulin resistance and reduces hepatic fat in obese, nondiabetic subjects[J]. Diabetes, 2019, 68(Suppl 1): 140-LB.
[42]	GAICH G, CHIEN JY, FU H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes[J]. Cell Metab, 2013, 18(3): 333-340. DOI: 10.1016/j.cmet.2013.08.005.
[43]	GENG L, LAM K, XU A. The therapeutic potential of FGF21 in metabolic diseases: From bench to clinic[J]. Nat Rev Endocrinol, 2020, 16(11): 654-667. DOI: 10.1038/s41574-020-0386-0.
[44]	WEI W, DUTCHAK PA, WANG X, et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ[J]. Proc Natl Acad Sci U S A, 2012, 109(8): 3143-3148. DOI: 10.1073/pnas.1200797109.